PMC:7105343 / 0-695 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T70662","span":{"begin":638,"end":640},"obj":"Body_part"},{"id":"T49296","span":{"begin":685,"end":689},"obj":"Body_part"},{"id":"T60073","span":{"begin":685,"end":687},"obj":"Body_part"}],"attributes":[{"id":"A39735","pred":"fma_id","subj":"T70662","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A93600","pred":"fma_id","subj":"T49296","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A19215","pred":"fma_id","subj":"T60073","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence\n\nAbstract\nBackground\nCancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.\n\nMethods\nUsing Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 block"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":72,"end":80},"obj":"Disease"},{"id":"T2","span":{"begin":142,"end":148},"obj":"Disease"},{"id":"T3","span":{"begin":178,"end":186},"obj":"Disease"},{"id":"T4","span":{"begin":242,"end":262},"obj":"Disease"},{"id":"T5","span":{"begin":426,"end":434},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005087"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence\n\nAbstract\nBackground\nCancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.\n\nMethods\nUsing Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 block"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T67949","span":{"begin":81,"end":82},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T8475","span":{"begin":192,"end":193},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5740","span":{"begin":363,"end":370},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence\n\nAbstract\nBackground\nCancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.\n\nMethods\nUsing Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 block"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":56,"end":61},"obj":"Chemical"},{"id":"T2","span":{"begin":344,"end":349},"obj":"Chemical"},{"id":"T3","span":{"begin":395,"end":400},"obj":"Chemical"},{"id":"T4","span":{"begin":533,"end":538},"obj":"Chemical"},{"id":"T5","span":{"begin":573,"end":581},"obj":"Chemical"},{"id":"T6","span":{"begin":638,"end":640},"obj":"Chemical"},{"id":"T8","span":{"begin":673,"end":683},"obj":"Chemical"},{"id":"T9","span":{"begin":685,"end":687},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_35341"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A7","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A10","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence\n\nAbstract\nBackground\nCancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.\n\nMethods\nUsing Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 block"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T54761","span":{"begin":590,"end":598},"obj":"http://purl.obolibrary.org/obo/GO_0070265"},{"id":"T2","span":{"begin":590,"end":598},"obj":"http://purl.obolibrary.org/obo/GO_0019835"},{"id":"T3","span":{"begin":590,"end":598},"obj":"http://purl.obolibrary.org/obo/GO_0008219"},{"id":"T4","span":{"begin":590,"end":598},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence\n\nAbstract\nBackground\nCancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.\n\nMethods\nUsing Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 block"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":120},"obj":"Sentence"},{"id":"T2","span":{"begin":122,"end":130},"obj":"Sentence"},{"id":"T3","span":{"begin":131,"end":141},"obj":"Sentence"},{"id":"T4","span":{"begin":142,"end":350},"obj":"Sentence"},{"id":"T5","span":{"begin":351,"end":435},"obj":"Sentence"},{"id":"T6","span":{"begin":437,"end":444},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence\n\nAbstract\nBackground\nCancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.\n\nMethods\nUsing Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 block"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":142,"end":148},"obj":"Phenotype"},{"id":"T2","span":{"begin":583,"end":589},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence\n\nAbstract\nBackground\nCancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.\n\nMethods\nUsing Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 block"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1","span":{"begin":72,"end":80},"obj":"Disease"},{"id":"7","span":{"begin":164,"end":172},"obj":"Species"},{"id":"8","span":{"begin":142,"end":148},"obj":"Disease"},{"id":"9","span":{"begin":178,"end":186},"obj":"Disease"},{"id":"10","span":{"begin":242,"end":262},"obj":"Disease"},{"id":"11","span":{"begin":426,"end":434},"obj":"Disease"},{"id":"20","span":{"begin":608,"end":612},"obj":"Gene"},{"id":"21","span":{"begin":638,"end":642},"obj":"Gene"},{"id":"22","span":{"begin":685,"end":689},"obj":"Gene"},{"id":"24","span":{"begin":573,"end":581},"obj":"Chemical"},{"id":"27","span":{"begin":583,"end":606},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"tao:has_database_id","subj":"1","obj":"MESH:C000657245"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"Tax:9606"},{"id":"A8","pred":"tao:has_database_id","subj":"8","obj":"MESH:D009369"},{"id":"A9","pred":"tao:has_database_id","subj":"9","obj":"MESH:C000657245"},{"id":"A10","pred":"tao:has_database_id","subj":"10","obj":"MESH:D012140"},{"id":"A11","pred":"tao:has_database_id","subj":"11","obj":"MESH:C000657245"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Gene:7124"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:3569"},{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"Gene:3552"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"MESH:D013256"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:D009336"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence\n\nAbstract\nBackground\nCancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.\n\nMethods\nUsing Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 block"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1","span":{"begin":21,"end":27},"obj":"UBERON:0002405"},{"id":"T2","span":{"begin":56,"end":61},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T3","span":{"begin":72,"end":80},"obj":"SP_7"},{"id":"T4","span":{"begin":178,"end":186},"obj":"SP_7"},{"id":"T5","span":{"begin":242,"end":253},"obj":"UBERON:0001004"},{"id":"T6","span":{"begin":303,"end":309},"obj":"UBERON:0002405"},{"id":"T7","span":{"begin":325,"end":331},"obj":"UBERON:0002405"},{"id":"T8","span":{"begin":344,"end":349},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T9","span":{"begin":395,"end":400},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T10","span":{"begin":426,"end":434},"obj":"SP_7"},{"id":"T11","span":{"begin":498,"end":504},"obj":"UBERON:0002405"},{"id":"T12","span":{"begin":533,"end":538},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T13","span":{"begin":573,"end":581},"obj":"CHEBI:35341;CHEBI:35341"},{"id":"T14","span":{"begin":638,"end":642},"obj":"PR:000001393"},{"id":"T15","span":{"begin":673,"end":683},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T856","span":{"begin":8,"end":13},"obj":"CHEBI:42768;CHEBI:42768"},{"id":"T48038","span":{"begin":21,"end":27},"obj":"UBERON:0002405"},{"id":"T78254","span":{"begin":56,"end":61},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T35077","span":{"begin":72,"end":80},"obj":"SP_7"},{"id":"T6651","span":{"begin":178,"end":186},"obj":"SP_7"},{"id":"T26298","span":{"begin":242,"end":253},"obj":"UBERON:0001004"},{"id":"T80056","span":{"begin":303,"end":309},"obj":"UBERON:0002405"},{"id":"T7780","span":{"begin":325,"end":331},"obj":"UBERON:0002405"},{"id":"T88791","span":{"begin":344,"end":349},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T63854","span":{"begin":395,"end":400},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T4393","span":{"begin":426,"end":434},"obj":"SP_7"},{"id":"T40457","span":{"begin":498,"end":504},"obj":"UBERON:0002405"},{"id":"T87395","span":{"begin":533,"end":538},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T27293","span":{"begin":573,"end":581},"obj":"CHEBI:35341;CHEBI:35341"},{"id":"T98626","span":{"begin":638,"end":642},"obj":"PR:000001393"},{"id":"T28930","span":{"begin":673,"end":683},"obj":"CHEBI:35222;CHEBI:35222"}],"text":"Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence\n\nAbstract\nBackground\nCancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.\n\nMethods\nUsing Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 block"}